SLC29A1 and Dravet syndrome: Given that cannabidiol is an ENT1 inhibitor [40], its anticonvulsant effects were proposed to be, at least in part, mediated by the increase in adenosine tone and the subsequent activation of A1R. Cannabidiol has been approved in the US and European Union for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex [109, 216], supporting the idea of ENT1 inhibition for epileptic treatment, even for drug-resistant types.